Unternehmensübersicht
Emergent BioSolutions Inc. operates as a life sciences company that develops and supplies preparedness and response solutions designed to address accidental, deliberate, and naturally occurring public health threats across the United States, Canada, and international markets. The enterprise functions within the healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on specialized pharmaceutical products rather than mass-market consumer goods. The company's operational scale is defined by a market capitalization of $410.54M and an annual revenue of $742.90M, supported by a workforce of 900 employees. These valuation and revenue figures indicate that the firm holds a mid-market position within its niche, reflecting a substantial revenue base relative to its market capitalization, a characteristic often seen in biotechnology and specialty drug firms where intangible assets and research pipelines influence valuation more than pure earnings multiples.
Finanzielle Gesundheit
The company reported a trailing twelve-month revenue of $742.90M, generating net income of $52.60M and an EBITDA of $208.90M. The significant gap between the revenue figure and the net income reveals a cost structure where operating expenses, likely including high research and development costs typical of the specialty drug sector, consume a substantial portion of gross profits before arriving at the bottom line. Free cash flow stands at $205.39M, which indicates a strong capacity to fund operations, invest in research, or manage liquidity without relying heavily on external financing. When analyzing the three key margin metrics, the gross margin is recorded at 49.4%, suggesting efficient production or sourcing of core products, while the operating margin stands at -15.2%, indicating that operating expenses currently exceed operating income, and the profit margin is 7.1%. On the balance sheet, total cash of $205.40M is held against total debt of $583.70M, resulting in a debt-to-equity ratio of 111.69, which characterizes the capital structure as highly leveraged rather than conservative. Despite the high leverage, the current ratio is 5.01, a metric that indicates robust short-term liquidity and the ability to cover immediate obligations with current assets. Return on Equity is 10.5% and Return on Assets is 5.3%, metrics that reveal how effectively management is utilizing shareholder equity and total assets to generate profits, respectively, with the ROE being notably higher than the ROA due to the financial leverage employed.
Bewertungsanalyse
The trailing P/E ratio is 8.53, while the forward P/E is significantly lower at 2.65. This disparity between the trailing and forward multiples implies that the market expects a substantial increase in future earnings relative to current levels, or conversely, that the current price reflects a low valuation based on past performance with high expectations for the future. The price-to-book ratio is 0.79, which indicates that the stock trades at a discount to its book value, suggesting the market may be pricing in risks or that the company's assets are not fully captured at fair market value on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.55 and the EV/EBITDA of 3.78 suggest the company is valued very cheaply relative to its sales and earnings power, which is common in cyclical or turnaround biotech situations. Regarding price volatility, the 52-week high was $14.06 and the low was $4.02; without a specific current share price provided in the source facts, the relative standing cannot be calculated, but the range demonstrates a wide trading band typical of high-beta stocks. The stock exhibits a beta of 2.44, which means the share price is expected to be roughly 2.44 times more volatile than the broader market, amplifying both potential gains and losses during periods of market movement.
Growth & Income
The revenue growth year-over-year is -23.6%, while earnings growth is listed as N/A due to the absence of comparable prior year data in the provided metrics. The negative revenue growth indicates a contraction in sales, whereas the absence of a defined earnings growth rate suggests that earnings management or one-time items may be obscuring the operational trend, making it difficult to discern if earnings are growing faster or slower than revenue at this specific moment. As the company does not distribute dividends, indicated by a dividend yield of N/A and a payout ratio of 0.0%, the firm retains all net income for reinvestment into growth initiatives, debt reduction, or shareholder buybacks rather than paying out cash to investors. Consequently, the overall growth and income profile for Emergent BioSolutions Inc. is characterized by a lack of current income distribution and a reliance on capital appreciation driven by potential future earnings recovery and revenue stabilization, rather than a steady stream of dividend income.